[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"smell-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:smell-dysfunction":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,71,107,135,156,181],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100616725",false,"NCT07309341","Effects of Isotretinoin on Smell","Effects of Isotretinoin on Nasal Mucociliary Clearance and Olfactory Function","Inclusion Criteria:\n\n* Diagnosed with acne and scheduled to start oral isotretinoin as part of routine dermatology care\n* Willing to participate and able to give informed consent\n* Not currently smoking\n* No history of allergic rhinitis, sinusitis, or active upper respiratory infection\n* No medical condition known to affect the sense of smell\n\nExclusion Criteria:\n\n* Younger than 18 years or older than 45 years\n* Current cigarette smoking\n* History of chronic sinonasal disease\n* Any condition that would prevent completing the smell test\n* Not willing to continue participation or withdrawal of consent at any time","ALL","18 Years","45 Years",{"count":19,"type":20},54,"ESTIMATED","INTERVENTIONAL",[23],"NA","Isotretinoin is a common medicine used to treat moderate to severe acne. It often causes dryness of the skin and the inside of the nose. Because a normal sense of smell depends on a healthy nasal lining, this dryness may affect how well a person can smell.\n\nThis study will examine whether isotretinoin treatment changes the sense of smell in adults with acne. Before starting isotretinoin, participants will complete a standardized smell test and two short questionnaires about nasal symptoms and quality of life: the Nasal Obstruction Symptom Evaluation (NOSE) scale and the 22-item Sino-Nasal Outcome Test (SNOT-22). After at least 4 weeks of treatment, the same smell test and questionnaires will be repeated.\n\nBy comparing results before and after treatment, the study will test the hypothesis that isotretinoin has a negative effect on olfactory function and may reduce patients' ability to smell.",[26],"Smell Dysfunction",[28,29,30],"olfaction","smell disfunction","isotretinoin","RECRUITING","2026-06-29",{"date":34,"type":35},"2026-06-30","ACTUAL",{"date":37,"type":35},"2025-06-01",{"date":39,"type":20},"2026-08-01",{"name":41,"class":42},"Uşak University","OTHER",1,{"id":45,"slug":46,"hasResults":10,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":43},"100594560","olfactory-biopsies-100594560","NCT07021040","Olfactory Biopsies","Analysis of Human Olfactory Biopsies","Group 1: Alzheimer's study\n\nInclusion Criteria:\n\n* Between the ages of 18 and 80\n* Pre-clinical AD (this cohort consists of subjects who have normal cognitive testing and function, but have positive AD biomarkers);\n* Symptomatic AD (a confirmed diagnosis of Alzheimer's or dementia who are capable of understanding and signing the consent document)\n\nExclusion Criteria:\n\n* Advanced Alzheimer's\u002Fdementia\n* Self-reported or known allergy to Afrin or Tetracain HCL (or related class of drugs)\n* Active Rhinosinusitis symptoms\n* Other known sinonasal disease history that would preclude biopsy (i.e prior sinus or skull base surgery directly impacting this anatomic region, sinonasal neoplasm in this anatomic region, olfactory cleft polyps)\n* Parkinson's disease\n* Unable or willing to complete the nasal endoscopy procedure.\n* Unable to read or speak English\n* Unable to provide legally effective consent\n\nGroup 2: Act-seq study or Non-AD controls\n\nInclusion Criteria:\n\n* Age 18 years or older\n* Patients being seen for rhinology or olfactory disorders\n* Patients having unrelated endoscopic nasal surgery\n\nExclusion Criteria:\n\n* Self-reported or known allergy to Afrin or Tetracain HCL (or related class of drugs)\n* Unable or willing to complete the nasal endoscopy procedure\n* Unable to read or speak English\n* Unable to provide legally effective consent",{"count":52,"type":20},125,[23],"This research study aims to investigate the function of the olfactory lining in the nasal cavity and its potential alterations in both healthy and diseased conditions. The olfactory lining is involved in the sense of smell.\n\nThe purpose of this study is to collect tissue from the nasal cavity.",[56,57,26],"Alzheimer Disease","Smell Loss",[59,60,61],"act-seq","nasal biopsy","RNA-seq","2026-06-11",{"date":64,"type":35},"2026-06-12",{"date":66,"type":35},"2025-01-06",{"date":68,"type":20},"2029-07-31",{"name":70,"class":42},"Duke University",{"id":72,"slug":73,"hasResults":10,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":43},"100504979","phase-2-study-of-chemosensory-enhancement-through-neuromodulation-training-scent-for-long-covid-100504979","NCT05855369","Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)","A Randomized Controlled Trial of Smell Training and Trigeminal Nerve Stimulation in the Treatment of COVID-related Persistent Smell Loss","Inclusion Criteria:\n\n* treatment-seeking for COVID-related persistent SL (anosmia, hyposmia, phantosmia or parosmia)\n* at least 1-month from SARS-coV-2 PCR-positive and\u002For rapid home-positive tests\n* normal sense of smell prior to COVID\n* naïve to both smell training (ST) and trigeminal nerve stimulation (TNS)\n* able to comprehend English and provide informed consent\n\nExclusion Criteria:\n\n* history of head injury (e.g. sport, accident, combat blast)\n* sinonasal condition (e.g. upper respiratory infection, rhinosinusitis, polyps)\n* neurological disorder (e.g. epilepsy, neurodegenerative disorder, narcolepsy)\n* serious mental illness (e.g. schizophrenia, bipolar, or other psychotic disorder)\n* suicidal ideation within the last month\n* current (≤6 months) heavy cigarette smoker (heavy defined as ≥ 10 pack-years)\n* oral\u002Fnasal steroids or other intranasal medications within the last month\n* immunomodulatory medications\n* pregnant or trying to become pregnant","65 Years",{"count":80,"type":20},145,[82,83],"PHASE2","PHASE3","Persistent smell loss that can include diminished or distorted smell function is a common symptom of long COVID syndrome. There are limited treatment options for long COVID-related smell loss. This study aims to determine the efficacy of two at-home treatments, smell training and non-invasive trigeminal nerve stimulation. This study requires participants to conduct daily at-home treatment sessions, attend three in-person study visits at the MUSC Department of Psychiatry and Behavioral Sciences, and complete electronic questionnaires over the 12-week trial, and again at the six-month timepoint. Participants in this trial may benefit directly with an improvement in sense of smell. However, participation may also help society more generally, as this study will provide new information about long COVID-related smell loss and its treatment.",[26,86,87],"Olfactory Disorder","Long COVID",[89,90,91,92,93,94,95,96,97],"COVID-19","Parosmia","Hyposmia","Anosmia","Phantosmia","Dysosmia","Olfactory Training","Neuromodulation","Non-invasive Brain Stimulation","2026-04-01",{"date":100,"type":35},"2026-04-02",{"date":102,"type":35},"2023-10-02",{"date":104,"type":20},"2028-05-31",{"name":106,"class":42},"Medical University of South Carolina",{"id":108,"slug":109,"hasResults":10,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":78,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":43},"100622687","the-effectiveness-of-steroid-nasal-drops-in-the-olfactory-cleft-combined-with-olfactory-training-for-patients-with-piod-100622687","NCT07386860","The Effectiveness of Steroid Nasal Drops in the Olfactory Cleft Combined With Olfactory Training for Patients With PIOD","Randomized Controlled Study on the Effectiveness of Steroid Nasal Drops in the Olfactory Cleft Combined With Olfactory Training for Patients With Post-infectious Olfactory Dysfunction","PIOD","Inclusion Criteria:\n\n1. Prospective enrollment of otolaryngology clinic patients aged 18-65 years with olfactory dysfunction. Diagnosis of post-infectious olfactory dysfunction (PIOD) will be based on the PPOD 2023 criteria. Participants must demonstrate olfactory impairment via Sniffin' Sticks testing, with TDI scores (sum of Threshold, Discrimination, and Identification) meeting: (1) Hyposmia: 16 \\\u003C TDI \\\u003C 30.75; (2) Anosmia: TDI ≤ 15.\n2. Willingness to participate and signed informed consent.\n\nExclusion Criteria:\n\n1. Use of systemic corticosteroids within 4 weeks or intranasal steroids within 2 weeks prior to enrollment.\n2. Severe nasal septum deviation, nasal tumors, acute upper respiratory infections, or uncontrolled allergic rhinitis.\n3. History of functional endoscopic sinus surgery or other nasal procedures within 12 months.\n4. Severe cardiovascular disease, hepatic\u002Frenal insufficiency, uncontrolled diabetes, or immune system disorders.\n5. Current or planned pregnancy.\n6. Investigator-determined inability to comply with study requirements (e.g., memory\u002Fbehavioral disorders, depression, heavy alcohol use, prior non-compliance).",{"count":116,"type":20},100,[23],"This study aims to evaluate the effectiveness of hormone nasal drops in the olfactory cleft combined with olfactory training for treating postinfectious olfactory dysfunction (PIOD). The main questions this clinical trial seeks to answer are:\n\nCan the combination of hormone nasal drops and olfactory training improve smell function better than olfactory training alone in PIOD patients? How does this combined treatment work?",[26],[121,122,123,124],"post-infectious olfactory dysfunction","olfactory training","steroid drops","combined therapy","NOT_YET_RECRUITING","2026-02-02",{"date":128,"type":35},"2026-02-04",{"date":130,"type":20},"2026-03-01",{"date":132,"type":20},"2028-12-31",{"name":134,"class":42},"Peking University Third Hospital",{"id":136,"slug":137,"hasResults":10,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":78,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":154,"leadSponsor":155,"locationsCount":43},"100622688","the-efficacy-of-olfactory-cleft-steroid-drops-in-patients-with-crs-with-olfactory-cleft-obstruction-100622688","NCT07386873","The Efficacy of Olfactory Cleft Steroid Drops in Patients With CRS With Olfactory Cleft Obstruction","Randomized Controlled Trial on the Efficacy of Olfactory Cleft Steroid Drops in Patients With Chronic Rhinosinusitis With Olfactory Cleft Obstruction","Inclusion Criteria:\n\n1. Prospective enrollment of otolaryngology clinic patients aged 18-65 years with olfactory dysfunction. Diagnosis of chronic rhinosinusitis-related olfactory dysfunction is based on the EPOS 2020 guidelines. Participants must demonstrate olfactory impairment via Sniffin' Sticks testing, with TDI scores (sum of Threshold, Discrimination, and Identification) meeting:(1) Hyposmia: 16 \\\u003C TDI \\\u003C 30.75; (2) 3.Anosmia: TDI \\\u003C 15.\n2. Sinus CT scans confirming obstruction in the olfactory cleft region.\n3. Willingness to participate and signed informed consent.\n\nExclusion Criteria:\n\n1. Use of systemic corticosteroids within 4 weeks or intranasal steroids within 2 weeks prior to enrollment.\n2. Severe nasal septum deviation, nasal tumors, acute upper respiratory infections, or uncontrolled allergic rhinitis.\n3. Severe cardiovascular disease, hepatic\u002Frenal insufficiency, uncontrolled diabetes, or immune system disorders.\n4. Current or planned pregnancy.\n5. Investigator-determined inability to comply with study requirements (e.g., memory\u002Fbehavioral disorders, depression, heavy alcohol use, prior non-compliance).",{"count":19,"type":20},[23],"This study aims to compare the efficacy of steroid nasal drops targeting the olfactory cleft versus traditional intranasal steroid sprays in improving olfactory function in patients with chronic rhinosinusitis (CRS) with olfactory cleft obstruction. The main questions this clinical trial aims to answer are:\n\n1. Efficacy Comparison: Is olfactory improvement greater with olfactory cleft-targeted steroid nasal drops compared to standard nasal steroid sprays in CRS patients?\n2. Mechanism Exploration: How do changes in inflammatory markers, obstruction severity, and olfactory test results explain the potential benefits of this treatment approach?",[146,26],"Chronic Rhinosinusitis (CRS)",[148,149,150,151],"Olfactory dysfunction","Chronic rhinosinusitis","Steroid nasal drops","Olfactory cleft obstruction",{"date":128,"type":35},{"date":130,"type":20},{"date":132,"type":20},{"name":134,"class":42},{"id":157,"slug":158,"hasResults":10,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":164,"targetDuration":166,"studyType":167,"phases":4,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":43},"100551124","prospective-registery-of-smelltaste-clinic-earnosethroat-100551124","NCT06456008","Prospective Registery of Smell\u002FTaste Clinic Ear\u002FNose\u002FThroat","Prospective Registry of Outcome and Correlates of Chemosensory Dysfunction at the Smell & Taste Clinic of UZ Leuven","ProspeRo'Scent","Inclusion criteria:\n\n* The psychophysical testing as well as the questionnaires require a cooperative participant who can understand and follow instructions and communicate their choices.\n* Informed consent is necessary upon participation for prospective registry.\n\nThere are no exclusion criteria related to sex, gender, or ethnicity. There are no exclusion criteria related to medical history or prior treatments.",{"count":165,"type":20},500,"5 Years","OBSERVATIONAL","Smell\u002Ftaste disorders are common conditions with a significant impact on quality of life. In September 2021, a specific consultation for patients with smell and taste disorders was initiated at the ENT-HNS (ear, nose, and throat, head and neck surgery) department of UZ Leuven, partly in light of post-COVID-19 related smell disorders.\n\nWith this observational ambidirectional study, the investigators aim to better map smell\u002Ftaste disorders in the Belgian\u002FFlemish population. Using standard-of-care diagnostic tests and structured questionnaires, the investigators strive to gain more insight into the severity, impact, and progression\u002Fprognosis of smell\u002Ftaste disorders.",[86,170,26,171],"Taste Disorders","Smell Disorder","2025-12-09",{"date":174,"type":35},"2025-12-18",{"date":176,"type":35},"2022-12-06",{"date":178,"type":20},"2035-12-31",{"name":180,"class":42},"Universitaire Ziekenhuizen KU Leuven",{"id":182,"slug":183,"hasResults":10,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":43},"100467236","olfactory-training-on-smell-dysfunction-patients-in-hk-100467236","NCT05364125","Olfactory Training on Smell Dysfunction Patients in HK","Effect of Olfactory Training on Olfactory Dysfunction Patients in Hong Kong Population","Inclusion Criteria:\n\n* Olfactory dysfunction \\> 6 months and \\\u003C 5 years\n\nExclusion Criteria:\n\n* History of significant head injury (fracture, ICH)\n* History of brain surgery\n* History of nasal surgery\n* Active nasal disease\n* Active neurological disease\n* Poor premorbid status\u002F non-communicable patients\n* Mentally incompetent patients\n* \\\u003C18 years' old\n* Pregnancy\n* Hypersensitivity to the aromatic substance.","70 Years",{"count":190,"type":20},80,[23],"* Causes of olfactory dysfunction can be classified into conductive and sensorineural causes.\n* Conductive causes are mainly due to structural nasal problem, which can be treated by nasal surgery\n* Sensorineural causes included post-infection, post-head injury, post Head and Neck irradiation and other central nervous system diseases.\n* Olfactory Training is well established treatment for sensorineural olfactory dysfunction in foreign countries.\n* Olfactory Training by neurological chemosensory stimulation using aromatic substances delivered via electronic portable aromatic rehabilitation (EPAR) diffuser was proved to be effective treatment in COVID-19 related olfactory dysfunction in recent Hong Kong study.\n* However, there is a lack of local study on the effect of Olfactory Training in other non-COVID-19 sensorineural causes of olfactory dysfunction in Hong Kong population.",[194,195,92,91,196,57,26],"Olfaction Disorders","Smell Disorders","Olfactory Impairment","2025-05-28",{"date":199,"type":35},"2025-06-03",{"date":201,"type":35},"2022-07-01",{"date":203,"type":20},"2027-06-30",{"name":205,"class":42},"Pamela Youde Nethersole Eastern Hospital"]